Nomura Securities analyst M. Ian Somaiya trimmed his price target on Buy-rated Synageva BioPharma (NASDAQ: GEVA) to $140.00 (from $144.00) ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE